NASDAQ:VERA Vera Therapeutics Q3 2024 Earnings Report $42.46 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$43.70 +1.24 (+2.91%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vera Therapeutics EPS ResultsActual EPS-$0.85Consensus EPS -$0.64Beat/MissMissed by -$0.21One Year Ago EPSN/AVera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time8:00AM ETUpcoming EarningsVera Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Earnings HeadlinesMarshall Fordyce Sells 18,500 Shares of Vera Therapeutics (NASDAQ:VERA) StockJune 26 at 4:23 AM | americanbankingnews.comVera Therapeutics (VERA) Appears Attractive After Latest FDA AgreementJune 17, 2026 | finance.yahoo.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.June 29 at 1:00 AM | Weiss Ratings (Ad)Vera Therapeutics (VERA) Receives a Buy from Wells FargoJune 13, 2026 | theglobeandmail.comWill FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy NarrativeJune 8, 2026 | finance.yahoo.comA Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial AnalysisJune 8, 2026 | finance.yahoo.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Winnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery StoryFabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutMicron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Xcel Energy Stock Offers Stability as Electricity Demand Builds Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
